Abstract: This disclosure is directed to ophthalmic suspensions for dry eye and other ocular indications that provide long-lasting on eye benefits. The disclosure provides methods of increasing lipid layer thickness and methods of lubricating an eye. The disclosure also provides methods of maintaining integrity of an eye's tear film layers which increases the eye's lipid layer thickness and methods of recreating or building one or more layers of an eye's tear film.

Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.

Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.

Abstract: This disclosure is directed to ophthalmic suspensions for dry eye and other ocular indications that provide long-lasting on eye benefits. The disclosure provides methods of increasing lipid layer thickness and methods of lubricating an eye. The disclosure also provides methods of maintaining integrity of an eye's tear film layers which increases the eye's lipid layer thickness and methods of recreating or building one or more layers of an eye's tear film.

Abstract: This disclosure is directed to ophthalmic suspensions for dry eye and other ocular indications that provide long-lasting on eye benefits. The disclosure provides methods of increasing lipid layer thickness and methods of lubricating an eye. The disclosure also provides methods of maintaining integrity of an eye's tear film layers which increases the eye's lipid layer thickness and methods of recreating or building one or more layers of an eye's tear film.

Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.

Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.

Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.

Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.

Abstract: This disclosure is directed to ophthalmic suspensions for dry eye and other ocular indications that provide long-lasting on eye benefits. The disclosure provides methods of increasing lipid layer thickness and methods of lubricating an eye. The disclosure also provides methods of maintaining integrity of an eye's tear film layers which increases the eye's lipid layer thickness and methods of recreating or building one or more layers of an eye's tear film.

Abstract: This disclosure is directed to ophthalmic suspensions for dry eye and other ocular indications that provide long-lasting on eye benefits. The disclosure provides methods of increasing lipid layer thickness and methods of lubricating an eye. The disclosure also provides methods of maintaining integrity of an eye's tear film layers which increases the eye's lipid layer thickness and methods of recreating or building one or more layers of an eye's tear film.

Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.

Abstract: This disclosure is directed to an ophthalmic formulation for dry eye and other ocular indications that provides long-lasting benefits. The formulations described herein provide durable relief and last two to ten longer on the eye than currently marketed products. The disclosure also provides methods of alleviating the symptoms of dry eye, methods for delivering ophthalmic pharmaceuticals, and methods of manufacture of the long-lasting ophthalmic formulations.

Abstract: This disclosure is directed to an ophthalmic formulation for dry eye and other ocular indications that provides long-lasting benefits. The formulations described herein provide durable relief and last two to ten longer on the eye than currently marketed products. The disclosure also provides methods of alleviating the symptoms of dry eye, methods for delivering ophthalmic pharmaceuticals, and methods of manufacture of the long-lasting ophthalmic formulations.

Abstract: Embodiments disclosed herein include devices, systems, and methods for determining tear film break-up time and for detecting eyelid margin contact and blink rates, particularly for diagnosing, measuring, and/or analyzing dry eye conditions and symptoms. The apparatus and methods for determining tear film break-up time and for detecting eyelid margin contact and blink rates, particularly for diagnosing, measuring, and/or analyzing dry eye conditions and symptoms may employ ocular surface interferometry (OSI) devices or other imaging and display devices capable of imaging and displaying a picture of a patient's eye during tear film break-up time and blink rate related procedures.

Abstract: An apparatus providing heat for treatment of an eyelid includes a heater unit configured to apply heat directly to an outer surface of the eyelid when an electrical signal is applied to the heater unit. The heater unit is affixed directly to the outer surface of the eyelid using an adhesive. A temperature regulator applies the electrical signal to the heater unit in order to achieve heating of the outer surface of the eyelid to a specified temperature range. A method is also disclosed that comprises affixing a heater unit directly into contact with the outer surface of the eyelid using an the adhesive. A control signal is applied to the heater unit to generate heat to the outer surface of the eyelid and is maintained for a period of time until the outer surface of the eyelid is heated to a specified temperature range.

Abstract: A method of treating dry eye includes delivering light energy from outside an eyelid toward the eyelid, and maintaining the delivery of the light energy toward the eyelid for a period of time to soften an obstruction of at least one meibomian gland. The light energy may be delivered specifically to the obstruction in the at least one meibomian gland without physically contacting the at least one meibomian gland, or the light energy delivered toward the eyelid may conductively apply heat to the meibomian gland to melt the obstruction. A corresponding apparatus includes a light energy source positionable outside an eyelid and configured to deliver the light energy from outside an eyelid toward the eyelid, and a controller configured to control the light energy source to maintain the delivery of the light energy toward the eyelid for a period of time to soften the obstruction.

Abstract: Intraocular lenses and related assemblies and intraocular attachment methods are disclosed herein. In one embodiment, an intraocular lens assembly comprises a helical-shaped coil fastener to affix an intraocular lens to an iris to correct for astigmatism, presbyopia, and/or myopia or hyperopia. The helical-shaped coil fastener comprises a head and a helical wire extending from a bottom surface of the head and comprising a pointed tip opposite the head. The helical-shaped coil fastener is configured to be affixed to the iris by rotatable penetration of the iris, and thus can be removed from the iris by reverse rotation of the helical-shaped coil fastener. The helical-shaped coil fastener has a low volume, large surface area, low cross-sectional area of penetration, and an oblique angle of penetration. Thus, the helical-shaped coil fastener is easy to apply, easy to remove, minimizes tissue damage, maximizes stability, and minimizes penetration force.

Abstract: Intraocular lenses and related assemblies and intraocular attachment methods are disclosed herein. In one embodiment, an intraocular lens assembly comprises a helical-shaped coil fastener to affix an intraocular lens to an iris to correct for astigmatism, presbyopia, and/or myopia or hyperopia. The helical-shaped coil fastener comprises a head and a helical wire extending from a bottom surface of the head and comprising a pointed tip opposite the head. The helical-shaped coil fastener is configured to be affixed to the iris by rotatable penetration of the iris, and thus can be removed from the iris by reverse rotation of the helical-shaped coil fastener. The helical-shaped coil fastener has a low volume, large surface area, low cross-sectional area of penetration, and an oblique angle of penetration. Thus, the helical-shaped coil fastener is easy to apply, easy to remove, minimizes tissue damage, maximizes stability, and minimizes penetration force.

Abstract: This disclosure is directed to an ophthalmic formulation for dry eye and other ocular indications that provides long-lasting benefits. The formulations described herein provide durable relief and last two to ten longer on the eye than currently marketed products. The disclosure also provides methods of alleviating the symptoms of dry eye, methods for delivering ophthalmic pharmaceuticals, and methods of manufacture of the long-lasting ophthalmic formulations.